Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus PBZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus PBZ.
BROMPHENIRAMINE MALEATE vs PBZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antihistamine
Antihistamine